Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 2
1998 2
2004 1
2006 1
2008 1
2009 3
2010 1
2011 3
2012 8
2013 9
2014 7
2015 6
2016 6
2017 2
2018 7
2019 4
2020 6
2021 5
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Among authors: jonasova a. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Platzbecker U, et al. Among authors: jonasova a. Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048786 Clinical Trial.
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.
Minařík L, Pimková K, Kokavec J, Schaffartziková A, Vellieux F, Kulvait V, Daumová L, Dusilková N, Jonášová A, Vargová KS, Králová Viziová P, Sedláček R, Zemanová Z, Stopka T. Minařík L, et al. Among authors: jonasova a. Cells. 2022 Jan 11;11(2):223. doi: 10.3390/cells11020223. Cells. 2022. PMID: 35053339 Free PMC article.
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Kubasch AS, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Diaz JMT, De Renzis B, Götze KS, Huetter-Kroenke ML, Gourin MP, Slama B, Dimicoli-Salazar S, Cony-Makhoul P, Laribi K, Park S, Jersemann K, Schipp D, Metzeler KH, Tiebel O, Sockel K, Gloaguen S, Mies A, Chermat F, Thiede C, Sapena R, Schlenk RF, Fenaux P, Platzbecker U, Adès L. Kubasch AS, et al. Among authors: jonasova a. Leukemia. 2022 Oct;36(10):2519-2527. doi: 10.1038/s41375-022-01669-z. Epub 2022 Sep 7. Leukemia. 2022. PMID: 36071100 Free PMC article.
Pokroky v onkohematologii v 21. století.
Neuwirtová R, Klamová H, Špička I, Benešová K, Obrtlíková P, Jonášová A. Neuwirtová R, et al. Among authors: jonasova a. Vnitr Lek. 2013 Jul;59(7):622-3. Vnitr Lek. 2013. PMID: 23909270 Czech. No abstract available.
[Use of cyclosporin A in hematology].
Jonásová A, Neuwirtová R. Jonásová A, et al. Cas Lek Cesk. 1998 Aug 3;137(15):451-4. Cas Lek Cesk. 1998. PMID: 9748742 Review. Czech.
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
Kaisrlikova M, Vesela J, Kundrat D, Votavova H, Dostalova Merkerova M, Krejcik Z, Divoky V, Jedlicka M, Fric J, Klema J, Mikulenkova D, Stastna Markova M, Lauermannova M, Mertova J, Soukupova Maaloufova J, Jonasova A, Cermak J, Belickova M. Kaisrlikova M, et al. Among authors: jonasova a. Leukemia. 2022 Jul;36(7):1898-1906. doi: 10.1038/s41375-022-01584-3. Epub 2022 May 3. Leukemia. 2022. PMID: 35505182 Free PMC article.
75 results